Manufacturer Restrictions On 340B Discounts Cut Contract Pharmacy-Based Savings 23% Or More
Hospital survey seeks to determine the financial impact of manufacturer limits on the 340B discounts they provide on drugs dispensed through pharmacies acting under contract with the program's covered entities.
You may also be interested in...
Janssen's 2021 US price transparency report offers insights into why the company recently joined the growing number of major pharma manufacturers who are restricting 340B discounts to contract pharmacies participating in the program.
Data from the US Health and Human Services Department quantify the financial impact of manufacturer 340B “integrity” initiatives on hospitals and other providers over the past several months.
Federal court vacates enforcement letter to Lilly from HRSA, but the decision was not completely favorable to pharma. It also offers the view that the law does not allow manufacturers to restrict 340B discounts to hospitals using multiple contract pharmacies.